A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Completed
National Cancer Institute (NCI)
Phase 1
This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine
analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous
infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours
on subsequent cycles. The side effects are allowed to disappear for up to 28 days. This cycle
is repeated after evaluations and follow-ups, which are every 4 weeks, as long as the patient
benefits.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with
advanced cancer that has not responded to previous treatment.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with
advanced cancer that has not responded to previous treatment.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with
advanced cancer that has not responded to previous treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
